Advertisement

Topics

Minomic clinical study progresses for MILGa in prostate, bladder, and pancreatic cancer

02:30 EDT 29 Jun 2017 | Sciad Newswire

Australian immuno-oncology company Minomic International Ltd is proceeding to the second stage of its pioneering MILGa clinical trial of MiltuximabTM, a chimeric version of Minomic’s MIL-38 anti-Glypican1 antibody conjugated to the radioactive isotope 67Gallium.

Original Article: Minomic clinical study progresses for MILGa in prostate, bladder, and pancreatic cancer

NEXT ARTICLE

More From BioPortfolio on "Minomic clinical study progresses for MILGa in prostate, bladder, and pancreatic cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...